Marinus Pharmaceuticals Executive Compensation (FY23)
MRNS · Executive and director compensation, fiscal 2022 to 2023
The Marinus Pharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 27, 2026Latest filing (8-K): May 24, 2024
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
The Pay Desk is the free weekly executive pay briefing — one company at a time, every number traceable to a public filing.You’ll confirm on The Pay Desk’s sign-up page.
$1,500Get the executive brief
111 figures on this page: 106 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
What changed from fiscal 2022 to fiscal 2023
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Scott Braunstein: $3,131,996 → $3,214,100 (2.6% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Marinus Pharmaceuticals' chief executive and what were they paid?
Scott Braunstein was paid $3,214,100 in total compensation as President, Chief Executive Officer and Director for fiscal 2023. Braunstein's total moved 2.6% higher from the $3,131,996 reported for fiscal 2022.
What was Marinus Pharmaceuticals' say-on-pay result?
Shareholders recorded 77.7% support for the say-on-pay proposal at the meeting held May 22, 2024 for fiscal 2023.
Which companies are in Marinus Pharmaceuticals' peer group?
The disclosed peer group includes Albireo Pharma, Inc., Alector, Inc., Arcturus Therapeutics Holdings Inc., Cara Therapeutics, Inc. and Chimerix, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Scott Braunstein President, Chief Executive Officer and Director | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Joseph Hulihan Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Steven Pfanstiel Chief Operating Officer, Chief Financial Officer and Treasurer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Scott Braunstein President, Chief Executive Officer and Director | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Steven Pfanstiel Chief Operating Officer, Chief Financial Officer and Treasurer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Joseph Hulihan Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2023 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Joseph Hulihan | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Steven Pfanstiel | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Scott Braunstein | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2023
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Christine Silverstein | ◇ | — | — | — | — | — | ◇ |
Saraswathy V. Nochur, Ph.D | ◇ | — | — | — | — | — | ◇ |
Tim M. Mayleben | ◇ | — | — | — | — | — | ◇ |
Marvin H. Johnson Jr Lead independent director | ◇ | — | — | — | — | — | ◇ |
Seth H.Z. Fischer | ◇ | — | — | — | — | — | ◇ |
Elan Ezickson | ◇ | — | — | — | — | — | ◇ |
Charles Austin | ◇ | — | — | — | — | — | ◇ |
Scott Braunstein, M.D served on the board in fiscal 2023 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options and RSUs.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2023
- Albireo Pharma, Inc. symbol not shown
- Alector, Inc. ALEC
- Arcturus Therapeutics Holdings Inc. ARCT
- Cara Therapeutics, Inc. symbol not shown
- Chimerix, Inc. CMRX
- Chinook Therapeutics, Inc. KLRS
- CymaBay Therapeutics, Inc. PTGX
- Fulcrum Therapeutics, Inc. FULC
- Gelesis Holdings, Inc. symbol not shown
- Immunic, Inc. symbol not shown
- Mirum Pharmaceuticals, Inc. MIRM
- OptiNose, Inc. OPTN
- Phathom Pharmaceuticals, Inc. PHAT
- Rhythm Pharmaceuticals, Inc. RYTM
- Rigel Pharmaceuticals, Inc. RIGL
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2023 | May 22, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 24, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 25, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 26, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | May 27, 2020 | = | ◇ | ◇ | ◇ |
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
What this page does not include
Everything above is a fact Marinus Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Marinus Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
111 figures on this page: 106 cited to the filing that reported them, 5 calculated from figures it prints.
106 cited to the filing
5 calculated from the filing
Documents cited
- 0001104659-24-064904Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001558370-24-004691EXECUTIVE AND DIRECTOR COMPENSATION
- 0001558370-23-010572Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001558370-22-009360Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001104659-21-073212Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001104659-20-066366Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Marinus Pharmaceuticals executive compensation, FY2022–FY2023.” https://intel.velarion.ai/comp/MRNS (accessed 2026).
Short form: data: Velarion
The Marinus Pharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Marinus Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Marinus Pharmaceuticals discloses
The companies named in MRNS's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}